ES2193592T3 - Uso de derivados de la oxazolidinona para el tratamiento de la artritis. - Google Patents

Uso de derivados de la oxazolidinona para el tratamiento de la artritis.

Info

Publication number
ES2193592T3
ES2193592T3 ES98960157T ES98960157T ES2193592T3 ES 2193592 T3 ES2193592 T3 ES 2193592T3 ES 98960157 T ES98960157 T ES 98960157T ES 98960157 T ES98960157 T ES 98960157T ES 2193592 T3 ES2193592 T3 ES 2193592T3
Authority
ES
Spain
Prior art keywords
arthritis
treatment
oxazolidinone derivatives
psoriasis
oxazolidinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98960157T
Other languages
English (en)
Inventor
Donald H Batts
Roger G Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2193592T3 publication Critical patent/ES2193592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de una oxazolidinona seleccionada entre: (S)-N-[[3-[3-fluoro-4-[4-(hidroxiacetil)-1- piperazinil]-fenil]-2-oxo-5-oxazolidinil]metil]acetamida, (S)-N-[[3-[3-fluoro-4-(4-morfolinil)fenil]-2-oxo-5- oxazolidinil]metil]acetamida, [4(S)-cis]-(-)-N-[[3-[3-Fluoro-4-(tetrahidro-1-oxido- 2H-tiopiran-4-il)fenil]-2-oxo-5- oxazolidinil]metil]acetamida, N-((5S)-3-(3-fluoro-4-(4-(2-fluoroetil)-3- oxopiperacin-1-il)fenil)-2-oxooxazolidin-5- ilmetil)acetamida, (S)-N-[[3-[5-(3-piridil)tiofen-2-il]-2-oxo-5- oxazolidinil]metil]acetamida y (S)-N-[[3-[5-(4-piridil)pirid-2-il]-2-oxo-5- oxazolidinil]metil]acetamida y sales farmacéuticamente aceptables de los mismos para la fabricación de un medicamento para el tratamiento de artritis.
ES98960157T 1997-11-18 1998-11-10 Uso de derivados de la oxazolidinona para el tratamiento de la artritis. Expired - Lifetime ES2193592T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6568997P 1997-11-18 1997-11-18
US7129798P 1998-01-16 1998-01-16
US7366298P 1998-02-04 1998-02-04
US7524798P 1998-02-19 1998-02-19
US7767298P 1998-03-12 1998-03-12
PCT/US1998/023233 WO1999025344A1 (en) 1997-11-18 1998-11-10 Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy

Publications (1)

Publication Number Publication Date
ES2193592T3 true ES2193592T3 (es) 2003-11-01

Family

ID=27535698

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98960157T Expired - Lifetime ES2193592T3 (es) 1997-11-18 1998-11-10 Uso de derivados de la oxazolidinona para el tratamiento de la artritis.

Country Status (16)

Country Link
EP (1) EP1032386B1 (es)
JP (1) JP2001522886A (es)
KR (2) KR100574307B1 (es)
CN (2) CN1546030A (es)
AT (1) ATE233092T1 (es)
AU (1) AU743941B2 (es)
BR (1) BR9815615A (es)
CA (1) CA2303961A1 (es)
DE (1) DE69811717T2 (es)
DK (1) DK1032386T3 (es)
ES (1) ES2193592T3 (es)
HK (1) HK1036591A1 (es)
NZ (1) NZ504612A (es)
PT (1) PT1032386E (es)
SI (1) SI1032386T1 (es)
WO (1) WO1999025344A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753988B2 (en) 1998-06-05 2002-10-31 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
DE60030300T2 (de) * 1999-09-13 2007-08-30 Insite Vision, Inc., Alameda Topische behandlung zur vorbeugung von augeninfektionen
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
CN107456442A (zh) * 2016-06-03 2017-12-12 四川赛卓药业股份有限公司 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CA2174107C (en) * 1993-11-22 2005-04-12 Steven J. Brickner Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones

Also Published As

Publication number Publication date
AU743941B2 (en) 2002-02-07
EP1032386B1 (en) 2003-02-26
BR9815615A (pt) 2000-10-24
PT1032386E (pt) 2003-07-31
KR20050100009A (ko) 2005-10-17
DE69811717T2 (de) 2003-10-16
KR100589545B1 (ko) 2006-06-19
CN1546030A (zh) 2004-11-17
JP2001522886A (ja) 2001-11-20
KR20010032178A (ko) 2001-04-16
HK1036591A1 (en) 2002-01-11
NZ504612A (en) 2002-08-28
WO1999025344A1 (en) 1999-05-27
EP1032386A1 (en) 2000-09-06
DK1032386T3 (da) 2003-05-26
DE69811717D1 (de) 2003-04-03
SI1032386T1 (en) 2003-06-30
KR100574307B1 (ko) 2006-04-27
AU1582399A (en) 1999-06-07
CA2303961A1 (en) 1999-05-27
CN1142777C (zh) 2004-03-24
ATE233092T1 (de) 2003-03-15
CN1299281A (zh) 2001-06-13

Similar Documents

Publication Publication Date Title
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
DE50214206D1 (de) Kombinationstherapie substituierter oxazolidinone
ES2165441T3 (es) Inhibidores de calpaina y/o catepsina b oxazolidin sustituidos.
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
NZ307509A (en) Use of 1L agonists in the treatment of incontinence
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
SE9702564D0 (sv) New compounds
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ID21472A (id) Senyawa terbaru yang berguna sebagai agen pelindung saraf
DE69818294D1 (de) Oxazolidinone derivate und pharmazeutische zusammensetzungen
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ES2193592T3 (es) Uso de derivados de la oxazolidinona para el tratamiento de la artritis.
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
MY137595A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
ES2187156T3 (es) Terapia antidepresiva.
EP1304107A3 (en) Use of oxazolidinines derivatives for treating psoriasis
NZ331165A (en) Verotoxin pharmaceutical compositions and medical treatments therewith
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento